GSE133513 Sputum and blood transcriptomics characterization of the PDE4 inhibitor CHF6001 in COPD

Contributors : Mirco Govoni ; Michele Bassi ; Stefano Vezzoli ; Germano Lucci ; Aida Emirova ; Marie A Nandeuil ; Gianluigi Poli ; Stefano Petruzzelli ; Gera L Jellema ; Ebenezer Afolabi ; Brendan Colgan ; Brian Leaker ; Oliver Kornmann ; Kai M Beeh ; Henrik Watz ; Dave SinghSeries Type : Expression profiling by arrayOrganism : Homo sapiensThe aim of the present study was to characterize the gene expression profile of the phosphodiesterase-4 inhibitor CHF6001 on top of inhaled triple therapy in sputum cells and whole blood of chronic bronchitis patients. Samples for analyses were collected from a multicenter, three-period, three-way, placebo-controlled, double-blind, complete block crossover study. Eligible patients underwent three, 32-day treatment periods during which they received CHF6001 800 or 1600 µg twice daily (total daily doses of 1600 or 3200 µg) or matching placebo, all via multi-dose dry-powder inhaler (NEXThaler). Treatment periods were separated by a 28–42 day washout. Eligible patients were male or female, ≥40 years of age, current or ex-smokers with a smoking history ≥10 pac k-years, a diagnosis of COPD, post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥30% and
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research